Edition:
United Kingdom

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

17.50EUR
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
€17.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
62,080
52-wk High
€17.58
52-wk Low
€8.41

Select another date:

Thu, Feb 8 2018

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* ‍MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®​

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* ‍MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY​

BRIEF-Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic

* MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC

BRIEF-Mithra Pharmaceuticals Announces Injectables Agreement With GSP

* MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES

BRIEF-Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs

* FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS

BRIEF-Mithra Announces Valorization Of French Subsidiary

* SUCCESSFULLY DIVESTED ITS FRENCH AFFILIATE, MITHRA FRANCE‍​

BRIEF-Mithra Pharmaceuticals Announces Update On Clinical Study Progress For Estelle And Donesta‍​

* ANNOUNCES AN UPDATE ON THE CLINICAL STUDY PROGRESS FOR ESTELLE AND DONESTA‍​

BRIEF-Mithra Pharmaceuticals announces 36-month shelf life extension for Tibelia​

* ‍MITHRA ANNOUNCES 36-MONTH SHELF LIFE EXTENSION FOR TIBELIA​

BRIEF-Mithra Pharmaceuticals: ‍positive outcome of Myring commercial batch bioequivalence study​

* ‍POSITIVE OUTCOME OF MYRING COMMERCIAL BATCH BIOEQUIVALENCE STUDY

BRIEF-Mithra Pharmaceuticals ‍completes recruitment for Estelle Phase III study in US and Canada​

* ‍COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US AND CANADA​

Select another date: